Publications

Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis.

Pinho MP. et al, (2025), Cell Rep Med, 6

Quality of Life Analysis in Patients Submitted to Dendritic Cell Vaccination for High Grade Gliomas: Update Report on a Phase II DC Trial

Lepski GA. et al, (2025)

Profiling of Tumor-Infiltrating Immune Cells and Their Impact on Survival in Glioblastoma Patients Undergoing Immunotherapy with Dendritic Cells.

Peres N. et al, (2024), Int J Mol Sci, 25

A robust deep learning workflow to predict CD8 + T-cell epitopes.

Lee CH. et al, (2023), Genome Med, 15

Adjuvant Vaccination with Allogenic Dendritic Cells Significantly Prolongs Overall Survival in High-Grade Gliomas: Results of a Phase II Trial.

Lepski G. et al, (2023), Cancers (Basel), 15

Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma.

Ma R. et al, (2022), Neuro Oncol, 24, 2093 - 2106

Near-Complete Remission of Glioblastoma in a Patient Treated with an Allogenic Dendritic Cell-Based Vaccine: The Role of Tumor-Specific CD4+T-Cell Cytokine Secretion Pattern in Predicting Response and Recurrence.

Pinho MP. et al, (2022), Int J Mol Sci, 23

HLA-dependent variation in SARS-CoV-2 CD8 + T cell cross-reactivity with human coronaviruses.

Buckley PR. et al, (2022), Immunology, 166, 78 - 103

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.

COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk . and COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium ., (2022), Cell, 185, 916 - 938.e58

A robust deep learning platform to predict CD8+ T-cell epitopes

Lee C. et al, (2022)

HLA-dependent variation in SARS-CoV-2 CD8+ T cell cross-reactivity with human coronaviruses

Buckley P. et al, (2021)

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium . et al, (2021)

Potential CD8+ T Cell Cross-Reactivity Against SARS-CoV-2 Conferred by Other Coronavirus Strains.

Lee CH. et al, (2020), Front Immunol, 11

CD8+ T cell cross-reactivity against SARS-CoV-2 conferred by other coronavirus strains and influenza virus

Lee C. et al, (2020)

Frequency determination of breast tumor-reactive CD4 and CD8 T cells in humans: unveiling the antitumor immune response.

Pinho MP. et al, (2019), Oncoimmunology, 8

Cookies on this website

Search results (24)